Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTB-3550 TriKE
- Development stage
- Discontinued
- Lead developer
- GT Biopharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
GTB-3550 TriKE is a first-generation tri-specific killer engager (TriKE) developed for the treatment of relapsed/refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other CD33-positive hematologic malignancies. It is a single-chain recombinant fusion protein composed of the variable regions of anti-CD16 and anti-CD33 antibodies linked to a modified form of human interleukin 15 (IL-15). The molecule simultaneously binds CD16 on natural killer (NK) cells and CD33 on tumor cells while delivering an IL-15 signal to activate and expand NK cells. This design aims to enhance NK cell-mediated cytotoxicity against cancer cells without requiring exogenous cell therapy or combination drugs. Clinical studies demonstrated reductions in bone marrow blast levels in AML/MDS patients with good tolerability; however, development was discontinued in favor of more advanced second-generation molecules[1][3][5][6][7][9].
- Brand names
- GTB-3550 TriKEGTB3550 TriKEGTB 3550 TriKE
- Other names
- GTB 3550GTB3550GTB-3550
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FCGR3B (Fc gamma receptor III)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on GTB-3550 TriKE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTB-3550 TriKE.